TerminatedNot applicableNCT02960399
Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
Studying Agammaglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of South Florida
- Principal Investigator
- Jennifer Leiding, MDUniversity of South Florida
- Intervention
- Zostavax®(biological)
- Enrollment
- 2 enrolled
- Eligibility
- 60 years · All sexes
- Timeline
- 2015 – 2017
Study locations (1)
- University of South Florida, St. Petersburg, Florida, United States
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02960399 on ClinicalTrials.govOther trials for Agammaglobulinemia
Additional recruiting or active studies for the same condition.